Cryoport Q2 revenue rises 8% to $49.0 million; adjusted EBITDA turns positive
Cryoport reported second-quarter 2026 revenue of $49.0 million, up 8% from $45.5 million a year earlier, and a loss from continuing operations that narrowed to $8.3 million from $12.0 million. Adjusted EBITDA from continuing operations was $0.4 million, compared with negative $0.9 million a year earlier. The year-ago period included a $120.9 million gain from the sale of the CRYOPDP courier business, so the reported net loss of $8.3 million compares with net income of $108.9 million in Q2 2025.
Key points
- Q2 2026 total revenue was $49.0 million, up 8% year-over-year; Life Sciences Services revenue rose 15% to $28.0 million.
- Loss from continuing operations was $8.3 million for Q2 2026, compared with $12.0 million for Q2 2025.
- Total gross margin was 46.6% for Q2 2026, compared with 47.0% for Q2 2025.
- Cryoport held $396.7 million in cash, cash equivalents, and short-term investments as of June 30, 2026.
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.